3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
4
Waldenstrom Macroglobulinemia
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, B-Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
4
fludarabine
3
acalabrutinib
3
pirtobrutinib
2
obinutuzumab
2
ibrutinib
2
Rituximab
2
ricolinostat
1
idelalisib
1
fludarabine phosphate
1
Vincristine
1
Prednisone
1
Mesna
1
Leukapheresis
1
Doxorubicin
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, B-Cell
×
ARQ531
×
30 days
×
Clear all
NCT04728893
2026-06-12
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2
Recruiting
490 enrolled